TEPMETKO Continues To Strengthens Its Position As A Leading Metex14 Skipping NSCLC Therapy Delveinsight
With increasing biomarker-driven cancer treatments, TEPMETKO benefits from growing adoption in precision oncology. Competition from other MET ...
The Manila Times3h
Foghorn Therapeutics Provides Financial Update for 2024 and 2025 Strategic Outlook
Selective degradation of ARID1B achieved. Earlier this year, Foghorn announced that the company has achieved selective degradation of ARID1B and will provide a program update during 2025.